{"name":"ImmunoGen, Inc.","slug":"immunogen-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":115447000,"revenueGrowth":192.7,"grossMargin":0,"rdSpend":213370000,"netIncome":-222929000,"cash":348936000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"BB-10901","genericName":"BB-10901","slug":"bb-10901","indication":"Other","status":"phase_1"},{"name":"IMGN529","genericName":"IMGN529","slug":"imgn529","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"BB-10901","genericName":"BB-10901","slug":"bb-10901","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IMGN529","genericName":"IMGN529","slug":"imgn529","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE5EY1VkWE1EODd3cFVWVFQ0STA2aEtqNEJRbTVaZW1qdTJjVUlUZjY0ZV9tV1pZZDhjaWVJTktFaDNydS1nbjctLTlzWDNkYkZyQTJ2YmpGMXJ3bC1nTlIteUNab2JZVFo3QmV2bVhRdVI3aGM?oc=5","date":"2024-09-26","type":"pipeline","source":"Taylor & Francis Online","summary":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer - Taylor & Francis Online","headline":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQZWdxS1pIbkJXT01LWHY0RHBITEQydXRUcUZlaS00UWJIdnlwTi0wY1FpZWZrcEVPME9LcGtncEo5N1NrZTZDSkFRaC1DZTJUVEk1SVcwX1g5eEsxUXFHZGxXdU02QzVRTzFCSUlqUk1ZdWdNMXRJX3VwZ0l6UUVqZE1OVHhSczlKbnlMMjJvQ1Q0RGd0dzNBSWJtU0xRdlRRYWNtVk1BUWZ3OExBajVuUXFSYzM?oc=5","date":"2024-02-22","type":"deal","source":"Bloomberg.com","summary":"AbbVie Sells $15 Billion of Bonds to Buy ImmunoGen, Cerevel - Bloomberg.com","headline":"AbbVie Sells $15 Billion of Bonds to Buy ImmunoGen, Cerevel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNbmRudV91N3NKOW1zRHIzcVNaandYdWszbzcyNFduMnc1LW5vcnJhd2oyRWN5ZjBSSXY4SEMzbVA0MjF6WUtoZklPOFpHdFlBWXAyVEpjZlI3bFh3NDRDTTBqYTRxQnRkeTNZVk5FYU1oX3A0RGJ3RlFaeVAyQmYyWkx2ajVrb3dwRFZndndiTWo5NWU1TUlGRS1sWkJiR2hDS3A1TUhWUWJiUkh4clRlSVZBQQ?oc=5","date":"2024-02-12","type":"deal","source":"Fierce Pharma","summary":"AbbVie wraps up its $10.1B buyout of ImmunoGen well ahead of schedule - Fierce Pharma","headline":"AbbVie wraps up its $10.1B buyout of ImmunoGen well ahead of schedule","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPRnFqNkpHSDBsbmU1Mmtaa0NINmJ2d3ZIblkzd0JBM3prN0N1Y3BZaGZWcUtGMFBNMl9oYTRMd3VtMTVXUGNFbGF4eXh2d0FHWFdreklhZzVsdFZ2Mlo0YXZZU3BGU21PZ0JqZUh1RlVuMTVzVlJvb3FsaWI4cXBTV3locUhnQTJuLWwtS2JMOWYtdDhQOHN3?oc=5","date":"2023-11-30","type":"pipeline","source":"European Biotechnology Magazine","summary":"Takeover in ADC space: Abbvie snags ImmunoGen - European Biotechnology Magazine","headline":"Takeover in ADC space: Abbvie snags ImmunoGen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPcGc1eTVnNzcxMFdKWlkzSmtpTW8tUWlSTW04SWxndWVDS1ZZQTJBcTlBeW9ET0hnSFd5QUM2UC1sclJHOXV5X3JzQ3JjdFRlVE42WWJPa1lNNl9mcGNxZ0pNa0lQN0hqdjRaVHEtZkdDMUVRbkVtaVBGcXBWOFpiVmpFdDkxMkM5RGl0NlY1end2SEduSjlhQUVBdEJoQU55THhmbmw2ZllxVVhRQ0F0VDhnakVRdmNMSDNMaQ?oc=5","date":"2023-11-30","type":"pipeline","source":"Pharmaceutical Technology","summary":"AbbVie diversifies oncology portfolio with $10.1 bn ImmunoGen acquisition - Pharmaceutical Technology","headline":"AbbVie diversifies oncology portfolio with $10.1 bn ImmunoGen acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNSTAzeFBxWGlRVjBBcEdHbWhDaExnVFhXX1V5Q051aU5VSDZBdWJJNVdCejVUajR6VXRKTHczQ2p3YmowRXlHNlZLSEpubS0tNXltU1lxNDdOamVWVl85cERtOGJxTVJoUF9mX3ZGcHFXV2VMdHRyMzZzbERMOU1PZm05OHY4Vm5lS2oxVWZ0TTAxMHJ5cDBIeER4M19wNzV3Y2JpS1hOakdmU2Q2bUNF?oc=5","date":"2023-11-30","type":"deal","source":"Reuters","summary":"AbbVie seeks lift from 'guided missile' cancer drug with $10 bln ImmunoGen deal - Reuters","headline":"AbbVie seeks lift from 'guided missile' cancer drug with $10 bln ImmunoGen deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOMVlXeXlRYmdqcVBmTndHcEVfNGxVSGdMcTIzS2xZRkpGUzdXTEF1aWNWYW5haGxhRDhtLTJxMEFYR25QcTFoZzdSSXVBenVkN0M0MG9qNkxuZHg2VXBjMTZhQ1F2ZWtNaDQwejYwTDVRaDNHRkVtMmhrQUFQOFFPRGlMQjV3TTNBazlKRzJ5VGNILVJiUXZR?oc=5","date":"2023-11-30","type":"pipeline","source":"Yahoo Finance","summary":"Drugmaker AbbVie to spend over $10B on ImmunoGen to juice its cancer-fighting treatment portfolio - Yahoo Finance","headline":"Drugmaker AbbVie to spend over $10B on ImmunoGen to juice its cancer-fighting treatment portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPeUJMV0NqVWsyQnh5U1BiV3Q3ejJxRTB5WWd4UHFGTV9iVUZKaExzY015S204cnd5NGZoOXBnbnhOazNSREF6NFlBSDMzcy1FOGZSWkktdUFJd1g3b0xubkZyUmtLRFlTazdKWGVZUmlEVU5TczZYZmxJbEdKTGMtUzRxMUFqX2Y3ZDVzZ3I5U0VKSXdSRTg3dGhSdko3Z0ctZTMwSg?oc=5","date":"2023-11-30","type":"pipeline","source":"The Business Journals","summary":"AbbVie mum on plans for ImmunoGen employees, HQ - The Business Journals","headline":"AbbVie mum on plans for ImmunoGen employees, HQ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPMGxESF9ENnhGMm0wNERVazNqR2FnRUxpMTczYlR4N3dLdFlfM2FTSWNGLWEwX3hPSzBqZ3RoLXRUYzZ6eTZMNWxXQjN4QnZPSVRCZ1NjTHM5cHVSdUFyMjZfbGYwTmowelItY2VQZlNReXd0LUlMSzFGWWtuQy1HeEVYV2dTdVU2SDVOdU0weU5JM0U?oc=5","date":"2023-10-31","type":"pipeline","source":"Seeking Alpha","summary":"Analyzing The Acquisition Potential Of ImmunoGen (NASDAQ:IMGN) - Seeking Alpha","headline":"Analyzing The Acquisition Potential Of ImmunoGen (NASDAQ:IMGN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNQUtRcGF1NVpYM2RpUmNEcXAxenlkV2o0MlJWREZLTHhfVEYxME92NnZxRG1wUGJJa0VLOVJWSmk0cUZrSDdSTjJ2TXZ6U3FYbDRWa2tVM0N0VldKS1lkVXFsbjVVbDRJbWFqTzZObHdCRXg0NW50bUZ2bEsxX0hiWnR0M3h0VmZGR2FkQUdhbEQ3Wk83NU9UVDJhRQ?oc=5","date":"2023-08-28","type":"deal","source":"Contract Pharma","summary":"ImmunoGen, Takeda Partner to Commercialize ELAHERE in Japan - Contract Pharma","headline":"ImmunoGen, Takeda Partner to Commercialize ELAHERE in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPNzBXQXdydnlVQi14aDR1ZTYwRFo4b2tMVWUzM1VfMnM4VjlZcGxGb2ZpeFhraEZpQ0ZobkY0RFNtMzQ0NlFyOWJEZW5hbFQ1NDRIUU11WVhLZVEtbllyMGRQX3B4MlFUVmJzQ3RrQzRGNjZzUXhkaVBGdms2Z2o5anVxa040QkhpLWJ6TWF2WFNPM1Nrc3JKMnBpQWU?oc=5","date":"2022-11-16","type":"regulatory","source":"pharmaphorum","summary":"ImmunoGen ELAHERE wins accelerated FDA approval for ovarian cancer - pharmaphorum","headline":"ImmunoGen ELAHERE wins accelerated FDA approval for ovarian cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNaGo1ZDVrZVNMSG1wd2d2ZmFMV3pnWHFCeVYxVzhFREduNzJvWTNRQXQ5WGNaTW8zQTFETmlWcXBMbTc1emh1QkxOOHdqU0NEQ0ZFT01NcEFPdkt4T1ZJZldvbWtZM1BHdG9IZUxrbExlOUp6WFZHS0tkdFhvTWZOcWFZVFAyZ3FtOUpYQkRHZjV1OXZkYzZySkhXVGN1anozZi16SmUxejFJdjY0RzBnY0pPT1N2RVlKaVVyTHUya25IbU54WWJqZHh0UDNhY0I3OUtNODYwb0FzaWQyZXkzUU1NSmFxZU5VNjUxb3phV0JlS2t2NjNXeE5fOWNneERaS2U4eHdrSl9JbE9xR2dldXoyZVU2ZDZfSlluVlR6VkFJYWRtTkMzLV9hXzB2c1A0dzFrVGxXdw?oc=5","date":"2017-08-29","type":"deal","source":"PR Newswire","summary":"Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products - PR Newswire","headline":"Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commerci","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":115447000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":115447000,"period":"2017-12-31"},{"value":39448000,"period":"2017-12-31"},{"value":8480000,"period":"2017-09-30"},{"value":39020000,"period":"2017-06-30"},{"value":28499000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":213370000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-222929000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":348936000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}